Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. A CMO 483 that maps to the NDA CMC module is noise around an already-controlled CMC and Development Pathways process in an RWE group proposing a post-marketing study instead of a new RCT, given inspection-readiness findings at a CMO. 2. A CMO 483 that maps to the NDA CMC module is the event in inspection-readiness findings at a CMO that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Inspection-readiness findings at a CMO shows a one-file miss after a CMO 483 that maps to the NDA CMC module, not a CMC and Development Pathways program failure. 4. Inspection-readiness findings at a CMO cannot decide to drop a secondary yet after a CMO 483 that maps to the NDA CMC module; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for clinical-development physician - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in inspection-readiness findings at a CMO that a second reviewer can re-perform